UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 15

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 001-31938

 

 

ACORDA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

2 Blue Hill Plaza, 3rd Floor, Pearl River, New York

(914) 347-4300

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common Stock $0.001 par value per share

(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)

 

Rule 12g-4(a)(2)

 

Rule 12h-3(b)(1)(i)

 

Rule 12h-3(b)(1)(ii)

 

Rule 15d-6

 

Rule 15d-22(b)

 

Approximate number of holders of record as of the certification or notice date: 90

 

 

 


Pursuant to the requirements of the Securities Exchange Act of 1934, Acorda Therapeutics, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Date: August 13, 2024     By:  

/s/ Michael A. Gesser

    Name:   Michael A. Gesser
    Title:   Chief Financial Officer and Treasurer

Acorda Therapeutics (PK) (USOTC:ACORQ)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024 Haga Click aquí para más Gráficas Acorda Therapeutics (PK).
Acorda Therapeutics (PK) (USOTC:ACORQ)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024 Haga Click aquí para más Gráficas Acorda Therapeutics (PK).